Xcelerate, Inc. Announces the Sale of its Majority Interest in ESN Group
Xcelerate (OTC:XCRT) announced on October 9, 2025 the completed all-cash sale of its majority interest in the ESN Group of companies to Noble Labs Holdings, LLC.
The company said proceeds from the sale, together with funds from a recent private placement, will be used to refocus on its original mission: implementing an AI-aided medical technology and virtual health care program in Africa through majority-owned AfiyaSasa Africa, LLC, with additional development announcements expected in the near term.
Investors are directed to the company website for ongoing updates.
Xcelerate (OTC:XCRT) ha annunciato il 9 ottobre 2025 il completamento della vendita interamente in contanti della sua quota di maggioranza nel gruppo ESN delle società a Noble Labs Holdings, LLC.
La società ha dichiarato che i proventi della vendita, insieme ai fondi raccolti di recente tramite collocamento privato, saranno utilizzati per rifocalizzarsi sulla missione originaria: implementare un programma di tecnologia medica assistita dall'AI e assistenza sanitaria virtuale in Africa tramite la controllata maggioritaria AfiyaSasa Africa, LLC, con ulteriori annunci di sviluppo previsti a breve.
Gli investitori sono invitati a consultare il sito web della società per aggiornamenti continui.
Xcelerate (OTC:XCRT) anunció el 9 de octubre de 2025 la venta en efectivo de su participación mayoritaria en el grupo ESN de empresas a Noble Labs Holdings, LLC, ya completada.
La empresa dijo que los ingresos de la venta, junto con fondos de una reciente colocación privada, se utilizarán para reenfocarse en su misión original: implementar un programa de tecnología médica asistida por IA y atención médica virtual en África a través de la mayoría propietaria AfiyaSasa Africa, LLC, con anuncios de desarrollo adicionales esperados en el corto plazo.
Los inversores deben consultar el sitio web de la empresa para actualizaciones continuas.
Xcelerate (OTC:XCRT)은 2025년 10월 9일에 ESN 그룹의 지분 다수에 대한 전액 현금 매각이 Noble Labs Holdings, LLC에 의해 완료되었다고 발표했다.
회사는 매각 대금과 최근의 비공개 배정으로 조달된 자금을 사용하여 원래의 사명에 다시 집중할 것이라고 말했다: 아프리카에서의 AI 지원 의학 기술 및 가상 건강 관리 프로그램을 Majority 소유인 AfiyaSasa Africa, LLC를 통해 실행하고, 향후 개발 공지가 가까운 시일 내에 있을 것이라고 밝혔다.
투자자들은 지속적인 업데이트를 위해 회사 웹사이트를 참조하라고 지시받고 있다.
Xcelerate (OTC:XCRT) a annoncé le 9 octobre 2025 l’achèvement de la vente entièrement en liquidités de sa participation majoritaire dans le groupe ESN des sociétés à Noble Labs Holdings, LLC.
La société a déclaré que les produits de la vente, associée aux fonds d’un placement privé récent, seront utilisés pour se recentrer sur sa mission initiale : mettre en œuvre un programme de technologie médicale assistée par l’IA et de soins de santé virtuels en Afrique via la société majoritairement détenue AfiyaSasa Africa, LLC, avec de nouvelles annonces de développement prévues prochainement.
Les investisseurs sont priés de consulter le site web de la société pour les mises à jour continues.
Xcelerate (OTC:XCRT) gab am 9. Oktober 2025 den Abschluss des vollständigen Barverkaufs seiner Mehrheitsbeteiligung an der ESN-Gruppe von Unternehmen an Noble Labs Holdings, LLC bekannt.
Das Unternehmen sagte, dass die Erlöse aus dem Verkauf, zusammen mit Mitteln aus einer kürzlich erfolgten Privatplatzierung, verwendet werden, um sich erneut auf die ursprüngliche Mission zu fokussieren: die Implementierung eines von KI unterstützten medizinischen Technolog ies und virtuellen Gesundheitsprogramms in Afrika durch die Mehrheitsbeteiligung AfiyaSasa Africa, LLC, wobei in naher Zukunft weitere Entwicklungsankündigungen erwartet werden.
Investoren werden aufgefordert, die Website des Unternehmens für laufende Updates zu besuchen.
Xcelerate (OTC:XCRT) أعلن في 9 أكتوبر 2025 عن إتمام بيع نقدي كامل لحصة الأغلبية في مجموعة ESN من الشركات إلى Noble Labs Holdings, LLC.
وقالت الشركة إن عائدات البيع، إلى جانب أموال من طرح خاص حديث، ستستخدم لإعادة التركيز على مهمتها الأصلية: تنفيذ برنامج طبي تقني يعتمد على الذكاء الاصطناعي والرعاية الصحية الافتراضية في إفريقيا من خلال الشركة ذات الملكية الغالبة AfiyaSasa Africa, LLC، مع إعلانات تطوير إضافية متوقعة في المدى القريب.
يُوجَّه المستثمرون إلى موقع الشركة على الويب للحصول على تحديثات مستمرة.
Xcelerate (OTC:XCRT) 于 2025年10月9日 宣布已完成对 Noble Labs Holdings, LLC 的 ESN 集团多数股权的全额现金出售。
公司表示，出售所得以及最近私募的资金将用于重新聚焦其原始使命：通过多数持有的 AfiyaSasa Africa, LLC 在非洲实施一个 AI 辅助的医疗技术和虚拟医疗保健项目，并预计在不久的将来宣布更多开发事项。
投资者被指引前往公司官网获取持续更新。
- Completed all-cash sale of majority interest in ESN Group
- Proceeds plus recent private placement to fund AfiyaSasa Africa plan
- No longer retains majority interest in ESN Group
- Future execution depends on proceeds and private placement funding
MAULDIN, SC / ACCESS Newswire / October 9, 2025 / Xcelerate, Inc. (OTC Markets:XCRT) today announced the sale of its majority interest in the ESN Group of companies, including ESN Group, Inc. and California Skin Research, Inc to Noble Labs Holdings, LLC, a company that had previously provided funding and marketing support to ESN Group, Inc. The transaction was completed as an all-cash sale.
"We made a decision to divest these assets in order to re-focus our business on our original mission of implementing an AI aided medical technology and virtual health care program in Africa through our majority owned subsidiary, AfiyaSasa Africa, LLC," said Mike O'Shea, Xcelerate's Chief Executive Officer. "Proceeds from this sale, combined with funds raised in a recent private placement, will allow Xcelerate to re-implement this business plan. We anticipate making additional announcements on the development of this business in the near future."
Investors and stakeholders are encouraged to stay updated on the latest developments by visiting the Company's website at https://xcelerate.global.
ABOUT XCELERATE INC.
In May 2020, Xcelerate commenced implementation of a new business plan that encompasses two separate but related businesses within the medical industry, including (i) owning and licensing the rights to various forms of medical equipment and portfolio of patents, patents pending and technology licenses and (ii) development of virtual health technology to assist patients in developing countries obtain medical care by extending the reach of physicians through the use of that technology. For more information visit www.xcelerate.global or contact us at 854-900-2020 or email info@xcelerate.global.
SAFE HARBOR
This press release may contain forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things: (i) the Company's financing plans; (ii) trends affecting the Company's financial condition or results of operations; (iii) the Company's growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend," and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control, and actual results may differ materially from those projected in forward-looking statements resulting from various factors.
SOURCE: Xcelerate
View the original press release on ACCESS Newswire
FAQ
What did Xcelerate (XCRT) announce on October 9, 2025?
Who acquired Xcelerate's majority interest in ESN Group?
How will the sale affect Xcelerate's business plan for AfiyaSasa Africa?
Will Xcelerate provide more updates about the AfiyaSasa Africa program?
Where can investors find more information about Xcelerate (XCRT)?
